The strategic transition to in vivo gene editing is a significant move for Editas Medicine, indicating a clear focus and potential for future growth. The extension of the cash runway into Q2 2027 provides financial stability, which is positive for investors. The goal to achieve human proof of concept in two years suggests a clear timeline for potential breakthroughs, likely boosting investor confidence and positively impacting the stock price in the short term.